|
1
|
Small W Jr, Bacon MA, Bajaj A, Chuang LT,
Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR,
Viswanathan AN and Gaffney DK: Cervical cancer: A global health
crisis. Cancer. 123:2404–2412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xiao B, Xie Z, Guo L, Wu J and Zhang H:
Stomatin-like protein 2 expression is associated with clinical
survival in patients with cervical cancer. Int J Clin Exp Pathol.
8:1804–1809. 2015.PubMed/NCBI
|
|
3
|
de Sanjose S, Quint WG, Alemany L, Geraets
DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin
HR, et al: Human papillomavirus genotype attribution in invasive
cervical cancer: A retrospective cross-sectional worldwide study.
Lancet Oncol. 11:1048–1056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lecuru F, Bats A, Mathevet P, Querleu D,
Leblanc E, Darai PM, Marret H, Collin C, Chatellier G and Gilaizeau
F: Impact of sentinel lymph node biopsy on staging of early
cervical cancer: Results of a prospective, multicenter study. J
Clin Oncol. 27:CRA55062009. View Article : Google Scholar
|
|
5
|
Zhang Z, Wang J, Li J, Wang X and Song W:
MicroRNA-150 promotes cell proliferation, migration, and invasion
of cervical cancer through targeting PDCD4. Biomed Pharmacother.
97:511–517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gregory RI and Shiekhattar R: MicroRNA
biogenesis and cancer. Cancer Res. 65:3509–3512. 2011. View Article : Google Scholar
|
|
7
|
Esquela-Kerscher A and Slack F:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li GC, Cao XY, Li YN, Qiu YY, Li YN, Liu
XJ and Sun XX: MicroRNA-374b inhibits cervical cancer cell
proliferation and induces apoptosis through the p38/ERK signaling
pathway by binding to JAM-2. J Cell Physiol. 233:7379–7390. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang F, Shan S, Huo Y, Xie Z, Fang Y, Qi
Z, Chen F, Li Y and Sun B: MiR-155-5p inhibits PDK1 and promotes
autophagy via the mTOR pathway in cervical cancer. Int J Biochem
Cell Biol. 99:91–99. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kouji B, Iida M, Yanokura M, Kisu I, Iwata
T, Tominaga E, Tanaka K and Aoki D: MicroRNA in cervical cancer:
OncomiRs and tumor suppressor miRs in diagnosis and treatment.
ScientificWorldJournal. 2014:1780752014.PubMed/NCBI
|
|
11
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rasras S, Zibara K, Vosughi T and Zayeri
Z: Genetics and epigenetics of glioblastoma: Therapeutic
challenges. Clin Cancer Invest J. 7:43–49. 2018. View Article : Google Scholar
|
|
13
|
Takahashi RU, Prieto Vila M, Kohama I and
Ochiya T: Development of microRNA-based therapeutic approaches for
cancer patients. Cancer Sci. 110:1140–1147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chakraborty C, Sharma AR, Sharma G, Sarkar
BK and Lee SS: The novel strategies for next-generation cancer
treatment: miRNA combined with chemotherapeutic agents for the
treatment of cancer. Oncotarget. 9:10164–10174. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mittal A, Chitkara D, Behrman SW and
Mahato RI: Efficacy of gemcitabine conjugated and miRNA-205
complexed micelles for treatment of advanced pancreatic cancer.
Biomaterials. 35:7077–7087. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi S, Han L, Deng L, Zhang Y, Shen H,
Gong T, Zhang Z and Sun X: Dual drugs (microRNA-34a and
paclitaxel)-loaded functional solid lipid nanoparticles for
synergistic cancer cell suppression. J Control Release.
194:228–237. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Testoni D, Hayashi M, Cohen-Wolkowiez M,
Benjamin DK Jr, Lopes RD, Clark RH, Benjamin DK and Smith P:
Late-onset bloodstream infections in hospitalized term infants.
Pediatr Infect Dis J. 33:920–923. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie W, Sun F, Chen L and Cao X: MiR-96
promotes breast cancer metastasis by suppressing MTSS1. Oncol Lett.
15:3464–3471. 2018.PubMed/NCBI
|
|
19
|
Yang S, Chen Z, Fan D, Zhang R, Zhang Y
and Wu S: MiR-182-5p and miR-96-5p increased hepatocellular
carcinoma cell mobility, proliferation and cisplatin resistance
partially by targeting RND3. RSC Advances. 8:34973–34983. 2018.
View Article : Google Scholar
|
|
20
|
Fendler A, Jung M, Stephan C, Erbersdobler
A, Jung K and Yousef GM: The antiapoptotic function of miR-96 in
prostate cancer by inhibition of FOXO1. PLoS One. 8:e808072013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He C, Zhang Q, Gu R, Lou Y and Liu W:
miR-96 regulates migration and invasion of bladder cancer through
epithelial-mesenchymal transition in response to transforming
growth factor-β1. J Cell Biochem. 119:7807–7817. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma X, Shi W, Peng L, Qin X and Hui Y:
MiR-96 enhances cellular proliferation and tumorigenicity of human
cervical carcinoma cells through PTPN9. Saudi J Biol Sci.
25:863–867. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sternberg PW and Schmid SL: Caveolin,
cholesterol and Ras signalling. Nat Cell Biol. 1:E35–E37. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeong J, Thike AA, Ikeda M, Lim JCT, Lee
B, Nakamura S, Iqbal J and Tan PH: Caveolin-1 expression as a
prognostic marker in triple negative breast cancers of Asian women.
J Clin Pathol. 71:161–167. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duregon E, Senetta R, Bertero L, Bussolati
B, Annaratone L, Pittaro A, Papotti M, Marchiò C and Cassoni P:
Caveolin 1 expression favors tumor growth and is associated with
poor survival in primary lung adenocarcinomas. Tumor Biol.
39:1010428317694312017. View Article : Google Scholar
|
|
26
|
Zhou W, He L, Dai Y, Zhang Y, Wang J and
Liu B: MicroRNA-124 inhibits cell proliferation, invasion and
migration by targeting CAV1 in bladder cancer. Exp Ther Med.
16:2811–2820. 2018.PubMed/NCBI
|
|
27
|
Butz H, Szabó PM, Khella HW, Nofech-Mozes
R, Patocs A and Yousef GM: miRNA-target network reveals miR-124 as
a key miRNA contributing to clear cell renal cell carcinoma
aggressive behaviour by targeting CAV1 and FLOT1. Oncotarget.
6:12543–12557. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
Starbase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale clip-seq data. Nucleic Acids
Res. 42((Database issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okada S, Raja SA, Okerblom J, Boddu A,
Horikawa Y, Ray S, Okada H, Kawamura I, Murofushi Y, Murray F and
Patel HH: Deletion of caveolin scaffolding domain alters cancer
cell migration. Cell Cycle. 18:1268–1280. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Senetta R, Trevisan E, Rudà R, Maldi E,
Molinaro L, Lefranc F, Chiusa L, Lanotte M, Soffietti R and Cassoni
P: Caveolin 1 expression independently predicts shorter survival in
oligodendrogliomas. J Neuropathol Exp Neurol. 68:425–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shatz M and Liscovitch M: Caveolin-1: A
tumor-promoting role in human cancer. Int J Radiat Biol.
84:177–189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Goetz J, Lajoie P, M Wiseman S and Nabi I:
Caveolin-1 in tumor progression: The good, the bad and the ugly.
Cancer Metastasis Rev. 27:715–735. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Martini M, De Santis M, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang N, Zhou J, Li Q, Han F and Yu Z:
miR-96 exerts carcinogenic effect by activating
AKT/GSK-3β/β-catenin signaling pathway through targeting inhibition
of FOXO1 in hepatocellular carcinoma. Cancer Cell Int. 19:382019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song HM, Luo Y, Li DF, Wei CK, Hua KY,
Song JL, Xu H, Maskey N and Fang L: MicroRNA-96 plays an oncogenic
role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in
papillary thyroid carcinoma cells. Int J Clin Exp Pathol.
8:9889–9900. 2015.PubMed/NCBI
|
